HKEX-listed pharma, clinic operators and medical-services companies. Businesses with revenue, margin and cash flow today, priced against the same kind of observable transaction used across this site.
This hub covers healthcare companies that already sell something: a drug that is approved, a clinic visit, a device, a diagnostic. Pharma manufacturers, hospital and clinic networks, medical device makers, contract research organisations. The kind of business where the last annual report has a profit line, not just a trial readout.
That is the line that separates this hub from Biotech. Biotech covers Chapter 18A listings still pricing a pipeline against binary trial risk. This hub covers the companies on the other side of that line: revenue growing or shrinking for a reason a set of accounts can show, margins that move with volume or mix, cash flow that funds the next acquisition or gets returned through a buyback.
The method carries over unchanged. A convertible bond a private investor priced above the current stock. A buyback program run against the company's own cash flow. A licensing deal or an acquisition with a disclosed price tag. Each is a number a serious counterparty put on the business, sitting next to what the market currently pays for it. The work is checking whether the two agree, not forecasting which one moves.
The Company Spent HK$360M Buying Its Own Stock in Six Months. Profit Is Up 44%.
Gushengtang grew H1 2026 profit 44.2% and revenue 10.6%, and bought back HK$360M of its own shares in 51 purchases. The stock sits at HK$27.66 and the chart has spent ten weeks failing to hold a July breakout.
← All analyses